Cytoprotective effect of amifostine in radiation-induced acute mucositis - A retrospective analysis

Kouvaris, J; Kouloulias, V; Kokakis, J; Matsopoulos, G; Balafouta, M; Miliadou, A; Vlahos, L

dc.contributor.author	Kouvaris, J	en
dc.contributor.author	Kouloulias, V	en
dc.contributor.author	Kokakis, J	en
dc.contributor.author	Matsopoulos, G	en
dc.contributor.author	Balafouta, M	en
dc.contributor.author	Miliadou, A	en
dc.contributor.author	Vlahos, L	en
dc.date.accessioned	2014-03-01T01:17:40Z
dc.date.available	2014-03-01T01:17:40Z
dc.date.issued	2002	en
dc.identifier.issn	0378-584X	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/14615
dc.subject	Amifostine and radiotherapy	en
dc.subject	Cytoprotection	en
dc.subject	Mucositis	en
dc.subject	Retrospective study	en
dc.subject.classification	Oncology	en
dc.subject.other	amifostine	en
dc.subject.other	antihistaminic agent	en
dc.subject.other	hydrocortisone	en
dc.subject.other	methylprednisolone	en
dc.subject.other	tropisetron	en
dc.subject.other	adult	en
dc.subject.other	aged	en
dc.subject.other	article	en
dc.subject.other	asthenia	en
dc.subject.other	cancer radiotherapy	en
dc.subject.other	cell protection	en
dc.subject.other	colon carcinoma	en
dc.subject.other	controlled study	en
dc.subject.other	drug effect	en
dc.subject.other	endometrium carcinoma	en
dc.subject.other	esophagitis	en
dc.subject.other	fever	en
dc.subject.other	head and neck carcinoma	en
dc.subject.other	headache	en
dc.subject.other	human	en
dc.subject.other	hypotension	en
dc.subject.other	lung non small cell cancer	en
dc.subject.other	major clinical study	en
dc.subject.other	medical assessment	en
dc.subject.other	morbidity	en
dc.subject.other	mucosa inflammation	en
dc.subject.other	nausea	en
dc.subject.other	rash	en
dc.subject.other	rating scale	en
dc.subject.other	stomatitis	en
dc.subject.other	symptomatology	en
dc.subject.other	uterine cervix carcinoma	en
dc.subject.other	vomiting	en
dc.subject.other	xerostomia	en
dc.subject.other	Acute Disease	en
dc.subject.other	Adult	en
dc.subject.other	Aged	en
dc.subject.other	Amifostine	en
dc.subject.other	Esophagus	en
dc.subject.other	Female	en
dc.subject.other	Gastric Mucosa	en
dc.subject.other	Humans	en
dc.subject.other	Male	en
dc.subject.other	Middle Aged	en
dc.subject.other	Mouth Mucosa	en
dc.subject.other	Neoplasm Staging	en
dc.subject.other	Neoplasms	en
dc.subject.other	Radiation Injuries	en
dc.subject.other	Radiation-Protective Agents	en
dc.subject.other	Radiotherapy Dosage	en
dc.subject.other	Retrospective Studies	en
dc.subject.other	Stomatitis	en
dc.title	Cytoprotective effect of amifostine in radiation-induced acute mucositis - A retrospective analysis	en
heal.type	journalArticle	en
heal.identifier.primary	10.1159/000066055	en
heal.identifier.secondary	http://dx.doi.org/10.1159/000066055	en
heal.language	English	en
heal.publicationDate	2002	en
heal.abstract	Purpose: To study the cytoprotective impact of amifostine against acute radiation mucositis. Patients and Methods: A total of 117 cancer patients with carcinomas localized in pelvic organs, lung and head & neck were entered into this study. In a retrospective way, and in order to minimize the bias related to the investigator, 138 patients as historical controls were randomly selected from a database in our hospital. Acute radiation-induced gastrointestinal mucositis, esophagitis and stomatitis were assessed using the common toxicity criteria scale. The most severe grade recorded was evaluated as the final morbidity score for this patient. Mean toxicity score (MTS) was the mean value of recorded acute radiation toxicity. Mean interruption time (MIT) was the mean value of recorded interruption time due to radiation toxicity. Results: A significantly reduced severity of symptomatology related to oral, esophageal and rectal mucosa was noted in the amifostine group (group A) (p < 0.05, chi-square test). Furthermore, a significant reduction of MTS as well as MIT was observed in group A versus the historical controls (group B) (p < 0.05, Mann-Whitney U test). Conclusion: The administration of amifostine seems to protect patients against radiation-induced mucositis, but further investigation with randomized trials is needed.	en
heal.publisher	KARGER	en
heal.journalName	Onkologie	en
dc.identifier.doi	10.1159/000066055	en
dc.identifier.isi	ISI:000178174900010	en
dc.identifier.volume	25	en
dc.identifier.issue	4	en
dc.identifier.spage	364	en
dc.identifier.epage	369	en